Omeros Corporation Stock Price, News & Analysis (NASDAQ:OMER)

$18.26 -0.26 (-1.40 %)
(As of 11/22/2017 07:57 AM ET)
Previous Close$18.52
Today's Range$18.61 - $18.05
52-Week Range$8.71 - $27.09
Volume597,175 shs
Average Volume805,659 shs
Market Capitalization$889.03 million
P/E RatioN/A
Dividend YieldN/A
Beta3.53

About Omeros Corporation (NASDAQ:OMER)

Omeros Corporation logoOmeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Sector: Medical
  • Symbol: NASDAQ:OMER
  • CUSIP: 68214310
  • Web: www.omeros.com
Debt:
  • Debt-to-Equity Ratio: 8.99%
  • Current Ratio: 4.77%
  • Quick Ratio: 4.74%
Sales & Book Value:
  • Annual Sales: $41.62 million
  • Price / Sales: 21.06
  • Book Value: $0.19 per share
  • Price / Book: 96.11
Profitability:
  • Trailing EPS: ($1.28)
  • Net Income: $-66,740,000.00
  • Net Margins: -88.42%
  • Return on Assets: -42.19%
Misc:
  • Employees: 154
  • Outstanding Shares: 48,000,000
 

Frequently Asked Questions for Omeros Corporation (NASDAQ:OMER)

What is Omeros Corporation's stock symbol?

Omeros Corporation trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros Corporation's earnings last quarter?

Omeros Corporation (NASDAQ:OMER) released its quarterly earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.18. The biopharmaceutical company had revenue of $21.66 million for the quarter, compared to analyst estimates of $17.82 million. The firm's revenue was up 91.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.34) EPS. View Omeros Corporation's Earnings History.

When will Omeros Corporation make its next earnings announcement?

Omeros Corporation is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for Omeros Corporation.

Where is Omeros Corporation's stock going? Where will Omeros Corporation's stock price be in 2017?

8 Wall Street analysts have issued twelve-month price targets for Omeros Corporation's stock. Their forecasts range from $19.00 to $75.00. On average, they anticipate Omeros Corporation's stock price to reach $36.17 in the next twelve months. View Analyst Ratings for Omeros Corporation.

What are Wall Street analysts saying about Omeros Corporation stock?

Here are some recent quotes from research analysts about Omeros Corporation stock:

  • 1. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (11/15/2017)
  • 2. Maxim Group analysts commented, "Omeros announced that extended follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 were presented on November 4, 2017 at the American Society of Nephrology (ASN) Meeting in New Orleans. These data describe up to one-year follow-up of patients treated with OMS721 in the glomerulonephropathy Phase 2 clinical trial. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin- associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system." (11/6/2017)
  • 3. Cantor Fitzgerald analysts commented, "Omeros announced that it received breakthrough therapy designation for its MASP-2 inhibitor, OMS721, for the treatment of IgA nephropathy (IgAN)." (6/13/2017)
  • 4. Wedbush analysts commented, "The Wedbush View: With an emerging pipeline of rare disease focused products and OMIDRIA sales offsetting the company’s burn, we believe OMER to be an attractive investment for investors with a 2017-2018 horizon." (5/10/2017)

Who are some of Omeros Corporation's key competitors?

Who are Omeros Corporation's key executives?

Omeros Corporation's management team includes the folowing people:

  • Gregory A. Demopulos M.D., Chairman of the Board, President, Chief Executive Officer (Age 58)
  • Michael A. Jacobsen, Chief Accounting Officer, Vice President - Finance, Treasurer (Age 58)
  • Marcia S. Kelbon J.D., Vice President - Patent, General Counsel, Secretary (Age 57)
  • Thomas J. Cable, Lead Independent Director (Age 77)
  • Peter A. Demopulos M.D., Director (Age 61)
  • Ray Aspiri, Independent Director (Age 78)
  • Arnold C. Hanish, Independent Director (Age 69)
  • Leroy E. Hood M.D., Ph.D., Independent Director (Age 78)

Who owns Omeros Corporation stock?

Omeros Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (10.78%), Tocqueville Asset Management L.P. (1.00%), Stifel Financial Corp (0.82%), Bank of New York Mellon Corp (0.51%), Schwab Charles Investment Management Inc. (0.45%) and EAM Investors LLC (0.42%). Company insiders that own Omeros Corporation stock include Gregory A Md Demopulos, Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros Corporation.

Who sold Omeros Corporation stock? Who is selling Omeros Corporation stock?

Omeros Corporation's stock was sold by a variety of institutional investors in the last quarter, including Stoneridge Investment Partners LLC and Russell Investments Group Ltd.. Company insiders that have sold Omeros Corporation company stock in the last year include Gregory A Md Demopulos, Michael A Jacobsen and Thomas J Cable. View Insider Buying and Selling for Omeros Corporation.

Who bought Omeros Corporation stock? Who is buying Omeros Corporation stock?

Omeros Corporation's stock was bought by a variety of institutional investors in the last quarter, including Chicago Equity Partners LLC, EAM Investors LLC, Stifel Financial Corp, Schwab Charles Investment Management Inc., Ingalls & Snyder LLC, AMP Capital Investors Ltd, Bank of New York Mellon Corp and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Omeros Corporation.

How do I buy Omeros Corporation stock?

Shares of Omeros Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omeros Corporation's stock price today?

One share of Omeros Corporation stock can currently be purchased for approximately $18.26.

How big of a company is Omeros Corporation?

Omeros Corporation has a market capitalization of $889.03 million and generates $41.62 million in revenue each year. The biopharmaceutical company earns $-66,740,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. Omeros Corporation employs 154 workers across the globe.

How can I contact Omeros Corporation?

Omeros Corporation's mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.


MarketBeat Community Rating for Omeros Corporation (NASDAQ OMER)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  385 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  565
MarketBeat's community ratings are surveys of what our community members think about Omeros Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Omeros Corporation (NASDAQ:OMER)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $36.17 (98.06% upside)

Consensus Price Target History for Omeros Corporation (NASDAQ:OMER)

Price Target History for Omeros Corporation (NASDAQ:OMER)

Analysts' Ratings History for Omeros Corporation (NASDAQ:OMER)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017HC WainwrightInitiated CoverageBuy$30.00N/AView Rating Details
11/6/2017Maxim GroupReiterated RatingBuy$24.00N/AView Rating Details
11/2/2017Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
8/24/2017Cantor FitzgeraldReiterated RatingHold$15.00 -> $19.00HighView Rating Details
8/18/2017WedbushReiterated RatingOutperform$47.00LowView Rating Details
6/14/2017WBB SecuritiesReiterated RatingStrong-Buy$75.00HighView Rating Details
4/1/2017FBR & CoReiterated RatingBuyLowView Rating Details
3/17/2017Needham & Company LLCReiterated RatingBuy -> Buy$24.00 -> $22.00HighView Rating Details
10/17/2016S&P Equity ResearchBoost Price Target$7.65 -> $8.63N/AView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Omeros Corporation (NASDAQ:OMER)

Earnings by Quarter for Omeros Corporation (NASDAQ:OMER)

Earnings History by Quarter for Omeros Corporation (NASDAQ OMER)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
11/9/2017Q3 2017($0.34)($0.16)$17.82 million$21.66 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.35)($0.23)$14.63 million$17.15 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.35)($0.34)$13.32 million$12.26 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.40)($0.34)$11.64 million$11.30 millionViewListenView Earnings Details
8/9/2016Q216($0.50)($0.32)$9.80 million$10.00 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.54)$8.79 million$7.40 millionViewListenView Earnings Details
3/8/2016Q415($0.53)($0.52)$5.35 million$6.66 millionViewListenView Earnings Details
11/9/2015Q315($0.47)($0.46)$7.97 million$3.30 millionViewListenView Earnings Details
8/10/2015Q215($0.56)($0.44)$2.86 million$3.20 millionViewListenView Earnings Details
5/11/2015Q115($0.63)($0.51)$0.15 million$0.39 millionViewListenView Earnings Details
3/16/2015Q4($0.62)($0.61)$0.15 million$0.18 millionViewListenView Earnings Details
11/10/2014Q114($0.59)($0.54)$0.43 million$0.21 millionViewN/AView Earnings Details
8/11/2014Q2($0.56)($0.53)$0.37 million$0.45 millionViewN/AView Earnings Details
5/12/2014Q1($0.45)($0.45)$0.45 million$0.10 millionViewN/AView Earnings Details
3/13/2014Q413($0.38)($0.05)$0.17 million$1.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.44)($0.46)$0.14 million$0.20 millionViewN/AView Earnings Details
8/9/2013Q213($0.38)($0.48)$1.19 million$0.14 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.39)($0.40)$1.39 million$1.10 millionViewN/AView Earnings Details
3/18/2013($0.35)($0.30)$1.49 million$1.58 millionViewN/AView Earnings Details
11/9/2012Q312($0.34)($0.51)$1.42 million$1.40 millionViewN/AView Earnings Details
8/7/2012($0.36)($0.38)ViewN/AView Earnings Details
11/8/2011($0.39)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Omeros Corporation (NASDAQ:OMER)
2017 EPS Consensus Estimate: ($1.12)
2018 EPS Consensus Estimate: $0.33
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.36)($0.34)($0.35)
Q2 20172($0.34)($0.30)($0.32)
Q3 20172($0.29)($0.21)($0.25)
Q4 20172($0.28)($0.12)($0.20)
Q1 20181($0.02)($0.02)($0.02)
Q2 20181$0.03$0.03$0.03
Q3 20181$0.14$0.14$0.14
Q4 20181$0.18$0.18$0.18
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Omeros Corporation (NASDAQ:OMER)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Omeros Corporation (NASDAQ OMER)

Insider Ownership Percentage: 12.10%
Institutional Ownership Percentage: 45.38%
Insider Trades by Quarter for Omeros Corporation (NASDAQ:OMER)
Institutional Ownership by Quarter for Omeros Corporation (NASDAQ:OMER)

Insider Trades by Quarter for Omeros Corporation (NASDAQ OMER)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/16/2017Michael A JacobsenVPSell12,000$24.95$299,400.00View SEC Filing  
6/15/2017Michael A JacobsenVPSell24,000$21.20$508,800.00View SEC Filing  
4/12/2017Thomas J CableDirectorSell3,000$16.49$49,470.00View SEC Filing  
12/7/2016Gregory A Md DemopulosCEOSell306,124$10.66$3,263,281.84View SEC Filing  
12/6/2016Gregory A Md DemopulosCEOSell102,040$10.80$1,102,032.00View SEC Filing  
12/5/2016Gregory A Md DemopulosCEOSell102,040$10.71$1,092,848.40View SEC Filing  
12/2/2016Gregory A Md DemopulosCEOSell306,120$11.58$3,544,869.60View SEC Filing  
9/15/2016Marcia S KelbonVPSell16,000$10.91$174,560.00View SEC Filing  
8/15/2016Marcia S KelbonVPSell15,900$11.56$183,804.00View SEC Filing  
7/15/2016Marcia S KelbonVPSell15,900$11.50$182,850.00View SEC Filing  
6/15/2016Marcia S KelbonVPSell15,900$11.42$181,578.00View SEC Filing  
5/16/2016Marcia S KelbonVPSell15,900$9.94$158,046.00View SEC Filing  
4/15/2016Marcia S KelbonVPSell15,900$15.18$241,362.00View SEC Filing  
3/24/2016Thomas J CableDirectorSell2,000$14.81$29,620.00View SEC Filing  
12/22/2015Marcia S. KelbonVPSell15,900$15.00$238,500.00View SEC Filing  
9/4/2015Peter A Md DemopulosDirectorBuy3,962$12.68$50,238.16View SEC Filing  
7/15/2015Thomas J CableDirectorSell2,000$18.78$37,560.00View SEC Filing  
3/24/2015Thomas J CableDirectorSell2,000$24.50$49,000.00View SEC Filing  
6/24/2014Peter A Md DemopulosDirectorBuy6,153$16.20$99,678.60View SEC Filing  
6/2/2014Thomas J CableDirectorSell5,000$11.80$59,000.00View SEC Filing  
7/3/2013Thomas J CableDirectorSell5,000$5.21$26,050.00View SEC Filing  
4/10/2013Thomas J CableDirectorSell5,000$3.98$19,900.00View SEC Filing  
1/4/2013Ray AspiriDirectorBuy40,000$5.72$228,800.00View SEC Filing  
1/3/2013Arnold C HanishDirectorBuy2,000$5.58$11,160.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Omeros Corporation (NASDAQ OMER)

Source:
DateHeadline
Omeros: Impressive Pipeline Ignored By Markets - Seeking AlphaOmeros: Impressive Pipeline Ignored By Markets - Seeking Alpha
seekingalpha.com - November 21 at 9:01 AM
Omeros Corporation (OMER) Stock Rating Upgraded by Zacks Investment ResearchOmeros Corporation (OMER) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 19 at 11:36 PM
Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : November 16, 2017Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : November 16, 2017
finance.yahoo.com - November 18 at 10:35 AM
Omeros Corp. – Value Analysis (NASDAQ:OMER) : November 17, 2017Omeros Corp. – Value Analysis (NASDAQ:OMER) : November 17, 2017
finance.yahoo.com - November 18 at 10:35 AM
 Analysts Expect Omeros Corporation (OMER) Will Post Quarterly Sales of $22.23 Million Analysts Expect Omeros Corporation (OMER) Will Post Quarterly Sales of $22.23 Million
www.americanbankingnews.com - November 17 at 4:40 PM
Omeros Corporation (OMER) Given Average Recommendation of "Hold" by BrokeragesOmeros Corporation (OMER) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 12 at 3:56 PM
Omeros shares surge 17% after Q3 revenue beatOmeros shares surge 17% after Q3 revenue beat
finance.yahoo.com - November 12 at 11:17 AM
Can Omeros Top-Line Growth Continue?Can Omeros Top-Line Growth Continue?
finance.yahoo.com - November 12 at 11:17 AM
This Is Why Omeros Corporation Shares Are Rocketing 33% Higher TodayThis Is Why Omeros Corporation Shares Are Rocketing 33% Higher Today
finance.yahoo.com - November 12 at 11:17 AM
Omeros Story Continues to Get Better, but Reimbursement Risk RemainsOmeros Story Continues to Get Better, but Reimbursement Risk Remains
finance.yahoo.com - November 12 at 11:17 AM
This Biotech Just Rose By A Third On Its Earnings — But Is It In Trouble?This Biotech Just Rose By A Third On Its Earnings — But Is It In Trouble?
finance.yahoo.com - November 12 at 11:17 AM
Edited Transcript of OMER earnings conference call or presentation 9-Nov-17 9:30pm GMTEdited Transcript of OMER earnings conference call or presentation 9-Nov-17 9:30pm GMT
finance.yahoo.com - November 12 at 11:17 AM
Omeros Co. (OMER) Issues  Earnings ResultsOmeros Co. (OMER) Issues Earnings Results
www.americanbankingnews.com - November 10 at 12:08 AM
Omeros Corporation to Announce Third Quarter 2017 Financial Results on November 9, 2017Omeros Corporation to Announce Third Quarter 2017 Financial Results on November 9, 2017
finance.yahoo.com - November 7 at 8:09 AM
Extended Improvement in OMS721-Treated Patients with IgA Nephropathy Presented at American Society of Nephrology Annual MeetingExtended Improvement in OMS721-Treated Patients with IgA Nephropathy Presented at American Society of Nephrology Annual Meeting
finance.yahoo.com - November 7 at 8:09 AM
Omeros Corporation (OMER): Extended Follow-Up Data Evaluating OMS721 Shows Improvement in Patients with IgAOmeros Corporation (OMER): Extended Follow-Up Data Evaluating OMS721 Shows Improvement in Patients with IgA
finance.yahoo.com - November 7 at 8:09 AM
Omeros Corporation (OMER) Given Buy Rating at Maxim GroupOmeros Corporation (OMER) Given Buy Rating at Maxim Group
www.americanbankingnews.com - November 6 at 3:41 PM
ETFs with exposure to Omeros Corp. : November 3, 2017ETFs with exposure to Omeros Corp. : November 3, 2017
finance.yahoo.com - November 4 at 8:24 AM
ETFs with exposure to Omeros Corp. : November 3, 2017ETFs with exposure to Omeros Corp. : November 3, 2017
finance.yahoo.com - November 4 at 8:24 AM
Omeros Corporation (OMER) Downgraded by Cowen and CompanyOmeros Corporation (OMER) Downgraded by Cowen and Company
www.americanbankingnews.com - November 2 at 9:14 PM
Omeros Announces Upcoming Presentation of Clinical OMS721 Data at the American Society of Nephrology Annual MeetingOmeros Announces Upcoming Presentation of Clinical OMS721 Data at the American Society of Nephrology Annual Meeting
finance.yahoo.com - November 1 at 7:13 AM
Omeros Corporation (OMER) Set to Announce Quarterly Earnings on TuesdayOmeros Corporation (OMER) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 9:26 AM
Buying The Fear On This Small Biotech Stock - Seeking AlphaBuying The Fear On This Small Biotech Stock - Seeking Alpha
seekingalpha.com - October 31 at 7:26 AM
Omeros (OMER) Announces Further Positive Data from Ongoing Phase 2 Study of OMS721 in Patients with HCT-TMAOmeros (OMER) Announces Further Positive Data from Ongoing Phase 2 Study of OMS721 in Patients with HCT-TMA
www.streetinsider.com - October 28 at 8:35 PM
Maxim Group Reiterates Buy Rating for Omeros Corporation (OMER)Maxim Group Reiterates Buy Rating for Omeros Corporation (OMER)
www.americanbankingnews.com - October 27 at 10:22 PM
Omeros Stock Overcomes Obstacles, Set To Soar In Mid TermOmeros Stock Overcomes Obstacles, Set To Soar In Mid Term
seekingalpha.com - October 27 at 9:09 AM
Omeros Corporation: Additional Positive Data in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic MicroangiopathyOmeros Corporation: Additional Positive Data in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
finance.yahoo.com - October 27 at 9:09 AM
Notable Two Hundred Day Moving Average Cross - OMERNotable Two Hundred Day Moving Average Cross - OMER
www.thestreet.com - October 25 at 8:35 AM
Mid-Afternoon Market Update: Crude Oil Up Over 1%; Polaris Shares Surge On Upbeat EarningsMid-Afternoon Market Update: Crude Oil Up Over 1%; Polaris Shares Surge On Upbeat Earnings
feeds.benzinga.com - October 24 at 3:59 PM
Omeros Becomes Oversold (OMER)Omeros Becomes Oversold (OMER)
www.thestreet.com - October 24 at 8:00 AM
Omeros (OMER) Announces Successful OMS721 Treatment of PatientOmeros (OMER) Announces Successful OMS721 Treatment of Patient
www.streetinsider.com - October 22 at 7:51 PM
Omeros Corporation (OMER) Case Report Presented at EBMT Annual MeetingOmeros Corporation (OMER) Case Report Presented at EBMT Annual Meeting
finance.yahoo.com - October 21 at 7:23 AM
Omeros Corporation (OMER) Given a $24.00 Price Target at Maxim GroupOmeros Corporation (OMER) Given a $24.00 Price Target at Maxim Group
www.americanbankingnews.com - October 20 at 1:16 PM
Report of Successful OMS721 Treatment of Patient with Both Stem Cell Transplant-Associated Thrombotic Microangiopathy and Graft-versus-Host Disease Presented at EBMT Annual MeetingReport of Successful OMS721 Treatment of Patient with Both Stem Cell Transplant-Associated Thrombotic Microangiopathy and Graft-versus-Host Disease Presented at EBMT Annual Meeting
finance.yahoo.com - October 20 at 7:10 AM
ETFs with exposure to Omeros Corp. : October 18, 2017ETFs with exposure to Omeros Corp. : October 18, 2017
finance.yahoo.com - October 19 at 7:08 AM
Omeros Corporation (OMER) Given Average Rating of "Buy" by AnalystsOmeros Corporation (OMER) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 18 at 6:40 PM
BRIEF-Omeros Corp amends term loan agreementBRIEF-Omeros Corp amends term loan agreement
www.reuters.com - October 18 at 7:56 AM
Omeros Announces Upcoming Presentation of Clinical OMS721 Data at European Society for Blood and Marrow TransplantationOmeros Announces Upcoming Presentation of Clinical OMS721 Data at European Society for Blood and Marrow Transplantation
finance.yahoo.com - October 17 at 5:16 AM
Omeros Corporation (OMER) and Its Peers Financial ContrastOmeros Corporation (OMER) and Its Peers Financial Contrast
www.americanbankingnews.com - October 15 at 2:08 AM
Todays Research Reports on Stocks to Watch: Omeros Corporation and Therapix BiosciencesToday's Research Reports on Stocks to Watch: Omeros Corporation and Therapix Biosciences
finance.yahoo.com - October 9 at 8:23 PM
NovoCure Limited (NVCR) and Omeros Corporation (OMER) Head to Head ContrastNovoCure Limited (NVCR) and Omeros Corporation (OMER) Head to Head Contrast
www.americanbankingnews.com - October 8 at 6:28 AM
What You Must Know About Omeros Corporation’s (OMER) RisksWhat You Must Know About Omeros Corporation’s (OMER) Risks
finance.yahoo.com - October 7 at 6:57 AM
Omeros shares surge 10% after settlement with Endo delays generic to 2032 - MarketWatchOmeros shares surge 10% after settlement with Endo delays generic to 2032 - MarketWatch
www.marketwatch.com - October 5 at 1:45 PM
3 Stocks Up 30% or More Year to Date That Could Be Just Getting Started3 Stocks Up 30% or More Year to Date That Could Be Just Getting Started
finance.yahoo.com - October 5 at 1:45 PM
ETFs with exposure to Omeros Corp. : October 3, 2017ETFs with exposure to Omeros Corp. : October 3, 2017
finance.yahoo.com - October 5 at 1:45 PM
Omeros Announces Settlement of Infringement Suit Against ANDA Filer ParOmeros Announces Settlement of Infringement Suit Against ANDA Filer Par
finance.yahoo.com - October 5 at 1:45 PM
Omeros shares surge 10% after settlement with Endo delays generic to 2032Omeros shares surge 10% after settlement with Endo delays generic to 2032
finance.yahoo.com - October 5 at 1:45 PM
Omeros settles Omidria patent dispute with Par Pharma; shares up 6%Omeros settles Omidria patent dispute with Par Pharma; shares up 6%
seekingalpha.com - October 5 at 11:49 AM
Omeros Corporation (OMER) vs. The Competition Head to Head ContrastOmeros Corporation (OMER) vs. The Competition Head to Head Contrast
www.americanbankingnews.com - October 2 at 2:22 AM
Omeros Corporation (OMER) Receives Consensus Recommendation of "Buy" from BrokeragesOmeros Corporation (OMER) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 23 at 4:38 PM

Social Media

Financials

Chart

Omeros Corporation (NASDAQ OMER) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.